Semaglutide Shows Liver and Weight Gains in MASH

Real-world U.S. data suggest adults with MASH saw greater weight and liver enzyme declines on semaglutide 2.4 mg.

Updated on Nov. 7, 2026 in Weight Loss

Semaglutide Shows Liver and Weight Gains in MASH

Novo Nordisk announced real-world data from two retrospective studies on semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease. The results, presented at the AASLD, The Liver Meeting 2026 in Denver, Colorado, were drawn from US health system records and are relevant to adults with MASH and their care teams.

Why it matters

MASH is a serious liver condition that can progress to scarring and cirrhosis, and treatment options remain limited, so clinicians are watching closely for data on how existing therapies perform outside clinical trials. These observational studies add a view of how semaglutide 2.4 mg, which is FDA-approved under accelerated approval for adults with MASH and moderate-to-advanced liver scarring, performs in routine US practice.

These are retrospective observational studies, not randomized trials, drawing on PLATINUM-Truveta (2,873 semaglutide and 2,285 resmetirom initiators) and RHODIUM-2 (2,479 semaglutide initiators versus 70,702 non-initiators). Researchers used inverse probability of treatment weighting to reduce confounding, but baseline differences between groups remain a limitation.

The players

Novo Nordisk

A Danish pharmaceutical company known for its diabetes and obesity treatments, including the semaglutide-based medicines used in weight management and metabolic care.

AASLD, The Liver Meeting

The annual meeting of the American Association for the Study of Liver Diseases, a leading forum where hepatology researchers present advances in liver disease care.

Truveta

A health data company whose de-identified electronic medical record database supports observational research across US health systems.

The details

The studies used de-identified electronic medical records from US health systems covering June 2021 through March 2026, and applied statistical methods to adjust for differences between patients who did and did not receive semaglutide. In the six-month comparison, semaglutide 2.4 mg was linked to greater reductions than resmetirom in AST, a liver enzyme, and in some cardiometabolic measures. In the 12-month RHODIUM-2 analysis, people who started semaglutide also had larger declines in ALT, another liver enzyme, and in body weight than those who did not.

Data were drawn from records spanning June 2021 through March 2026.
Novo Nordisk announced the real-world data on November 6, 2026.

Health Landscape

MASH affects over 250 million people globally, and projections cited in the source anticipate an increase of over 160% in advanced MASH between 2015 and 2030. Semaglutide 2.4 mg's accelerated approval for MASH with moderate-to-advanced liver scarring places it among the few therapies with regulatory standing for this population, which is why observational data on it are being closely followed.

If you have been diagnosed with MASH or have fatty liver disease, these findings are worth raising with your doctor when discussing treatment options and monitoring. Because the studies are observational and non-randomized, they should be read as supporting context rather than a reason to change any medication on your own.

The takeaway

Real-world data suggest semaglutide 2.4 mg may be associated with meaningful weight and liver enzyme changes in adults with MASH, though retrospective designs limit firm conclusions. If you have MASH, ask your physician whether monitoring liver health and weight over time is appropriate for your situation.